ライフサイエンスコーパス: cancer

1 19%, P = 0.636) or rectal (FFT: 44% vs LFT: 35%, P = 0.330) cancer subgroups.

2 Since reovirus shows promise as a cancer therapy, efficient reovirus reverse genetics rescue wi

3 ranscriptional programs controlled by these isoforms affect cancer progression and outcomes.

4 The IO-LAHP NPs are able to induce efficient apoptotic cancer cell death both in vitro and in vivo through tumor-spe

5 first time, sensitive electrochemical detection of a breast cancer biomarker microRNA (miRNA), mir-21 was achieved via el

6 Tumor recurrence remains the main reason for breast cancer-associated mortality, and there are unmet clinical dem

7 er 25, 2013, 235 women undergoing PM for Stage 0-III breast cancer were randomized to undergo either standard PM ("no sha

8 ormed syngeneic studies with orthotopically injected breast cancer cells in wild-type and RAGE-knockout C57BL6 mice.

9 are highly effective in inhibiting ERalpha-negative breast cancer due at least in part to epigenetic reactivation of ERa

10 Here, we first demonstrated that breast cancer cells and pancreatic adenocarcinoma cells generated mi

11 ment of treatment solutions to benefit patients with breast cancer at high risk of recurrence.

12 ollected data on CHCs in all patients treated for childhood cancer at the St Jude Children's Research Hospital who surviv

13 Colorectal cancer originates within immunologically complex microenviron

14 a new primary endpoint in patients with advanced colorectal cancer.

15 Patients with lung or colorectal cancer often exhibit leukocytosis.

16 ed HuR as a small-molecule target for preventing colorectal cancer in high-risk groups such as those with familial adenom

17 Guidelines for cancer genetic testing based on family history may miss clini

18 ctionable genetic changes with established implications for cancer screening or prevention.

19 ion of patients responding to treatment in advanced gastric cancer.

20 ncludes more than 70% of patients newly diagnosed as having cancer in the United States.

21 Herein we show in a diverse array of human cancer cells that IMP2 overexpression stimulates and IMP2 eli

22 rix molecule that drives progression of many types of human cancer, but the basis for its actions remains obscure.

23 ptide hormone calcitonin is intimately connected with human cancer development and proliferation.

24 rs (CKIs), the expression of which is often dysregulated in cancer cells.

25 gineering with optogenetics to overcome critical hurdles in cancer immunotherapy.

26 ever, whether and to what extent TRAIL/TRAIL-R signaling in cancer cells can affect the immune microenvironment.

27 Previously, we found that in cancer cells derived from pancreatic ductal adenocarcinoma (P

28 ogenic mechanisms of overnutrition, a confirmed independent cancer risk factor, remain poorly understood.

29 xic treatments can play an important role in individualized cancer medicine.

30 CSCs initiate cancer formation and are linked to metastasis and resistance

31 tational hits (2nd Hit) transforms the expanding clone into cancer.

32 Invasive cancer cells interact with the surrounding extracellular matr

33 ated mitotic defects that likely contribute to HPV-mediated cancer progression.

34 ve OPSCC in 2010 to 2012 were identified using the National Cancer Data Base, which includes more than 70% of patients ne

35 yping technology to create scarless isogenic cell models of cancer variants in 1 month.

36 nosed with early-stage disease (American Joint Committee on Cancer [AJCC] stage 0, I, or II), and 48 (51.6%) were diagnos

37 in the tumor microenvironment that exert potent effects on cancer metastasis.

38 licated in acquired resistance to platinum drugs in ovarian cancer.

39 ng that Y10 phosphorylation-mediated LDHA activity promotes cancer cell invasion and anoikis resistance through redox hom

40 ose Guidelines are limited for genetic testing for prostate cancer (PCA).

41 The first evidence of prostate cancer lesion visualization in men using (68)Ga-NeoBOMB1 and

42 in, it is demonstrated that miR-194 is a driver of prostate cancer metastasis.

43 hSef-b gene delivery approach for the treatment of prostate cancer tumors, and possibly other carcinomas where Sef is dow

44 antigen (PSA) level, or (c) had a prior history of prostate cancer with increasing PSA level.

45 e of interest was the age-adjusted incidence of HPV-related cancer (both cervical and non-cervical) in all women in Engla

46 rch questions: (1) How accurate is teledermatology for skin cancer diagnosis compared with usual care (face-to-face [FTF]

47 oxygen concentration typical of most tissues, we find that cancer cells depend on high levels of the iron-sulfur cluster

48 or expression of phospho-deficient LDHA Y10F sensitized the cancer cells to anoikis induction and resulted in attenuated

49 estions that presented the risk of AK as not progressing to cancer had the lowest proportion of individuals who chose tre

50 osis guards (NF-kappaB, Bcl-2 and p53) in these NPs-treated cancer cells compared to 5-fluorouracil (5-FU) treated cells.